This is a single institution, open-label, phase I dose-escalation study in patients with advanced malignancies (NCT 01548144)....Among other patients with PR as best response to therapy, we had a clear cell renal cancer patient (−32%, PR) with a Kinase Insert Domain Receptor (KDR) p.C482R mutation previously treated with multiple lines of therapy including pazopanib monotherapy for a year (best response on monotherapy was SD).